Skip to main content
HCPCS J8612 · Level II · Part B drug

J8612: methotrexate (Xatmep), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J8612

Billing unit
2.5 MG
Oral methotrexate (xatmep)
ASP payment limit
$22.855
October 2026; -0.3% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0756
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J8612 is the Level II code for Methotrexate (xatmep), oral, 2.5 mg, billed per 2.5 MG. The Medicare Part B ASP payment limit for October 2026 is $22.855 per billing unit, down 0.3% from July 2026. Under OPPS it carries status indicator K in APC 0756. Oral drugs under Part B are payable only in the specific statutory categories (for example oral anticancer or antiemetic drugs with a self-administration exception), so the diagnosis and the regimen must match that category. Other HCPCS codes whose descriptor names methotrexate: J8611 (Jylamvo from Shorla Oncology Inc); J9260 (the code whose CMS descriptor names no specific product; billed per 50 mg). The ASP crosswalk maps 2 NDCs to it, sold as Xatmep by Azurity Pharmaceuticals, Inc. No current Billing and Coding Article lists J8612, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J8612 at $22.855 per 2.5 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $22.915 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J8612
QuarterPayment limitPerCoinsurance
October 2026$22.8552.5 MG20%
July 2026$22.9152.5 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J8612. Report the NDC in the claim's drug segment and bill the number of J8612 units that equals the quantity administered divided by 2.5 MG; the last column gives units per full package.

NDCs that crosswalk to J8612
NDCDrug nameLabelerPackage sizeBilling units / package
52652-2001-01XatmepAzurity Pharmaceuticals, Inc.120 × 1120
52652-2001-06XatmepAzurity Pharmaceuticals, Inc.60 × 160

Medically Unlikely Edits (MUE)

CMS publishes 1 MUE value for J8612.

MUE values for J8612 by setting
SettingMUE (units/DOS)MAICMS rationale
DME supplier363 Date of Service Edit: ClinicalPrescribing Information

MUE for J8612 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

Medicaid NCCI differs: the 2026 Q4 Medicaid MUE for J8612 is 36 units for practitioner claims (Medicare: no published value) and 36 units for outpatient hospital claims (Medicare: no published value). Compare both programs in the MUE lookup or read how Medicaid NCCI differs from Medicare.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J8612 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J8612 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J8612 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J8612 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J8612 carries status indicator K and is assigned to APC 0756, with a published national unadjusted payment of $22.855. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J8612 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $22.86 per 2.5 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J8612 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J8612

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J8612

What does HCPCS code J8612 describe?

J8612 is defined by CMS as "Methotrexate (xatmep), oral, 2.5 mg". Each billing unit represents 2.5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J8612 a CPT code?

No. J8612 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as methotrexate (Xatmep); CPT codes are five-character codes maintained by the AMA. On a Part B claim J8612 reports the drug itself in 2.5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J8612 in October 2026?

The ASP-based payment limit is $22.855 per 2.5 MG, with 20% beneficiary coinsurance. The July 2026 limit was $22.915. Commercial payers use their own fee schedules.

Which NDCs map to J8612?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Xatmep (Azurity Pharmaceuticals, Inc.). For example NDC 52652-2001-01 (package size 120) equals 120 billing units of J8612.

Does J8612 have NCCI bundling edits?

No active practitioner PTP pairs list J8612 as a column-1 or column-2 code in the v323r0 release.

J8612 vs J8611: what is the difference?

Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J8611 apart: Jylamvo from Shorla Oncology Inc. J8612 is billed per 2.5 mg, limit $22.855; J8611 is billed per 2.5 mg, limit $18.264. Report the code whose descriptor matches the product and setting in the record.

J8612 vs J9260: what is the difference?

Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J9260 apart: the code whose CMS descriptor names no specific product; billed per 50 mg. J8612 is billed per 2.5 mg, limit $22.855; J9260 is billed per 50 mg, limit $2.909, MUE 400. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.